Issue 11/2025
Popova, D., Dicheva, M., Kamenova, V, Sidova, S., Kotulova, V.
Clinic of Endocrinology and Metabolic diseases for the treatment of metabolic disorders
University hospital Queen Giovanna – ISUL , Medical university-Sofia
Currently, based on favorable proved effects of many nutrients, the nutraceutical approaches have been applied in clinical practice as the pharmaceutical approaches.
The three months clinical study on the application of the complex nutraceutical product contained omega-3 fatty acids, koenzyme Q 10 and selenium as nutrients with proved cardio protective, antioxidant and anti atherosclerotic effects in group of 34 clinical patients with average age 52,18 years, 21 female and 13 male with light to middle dyslipoproteinemias and metabolic syndrome in the Clinic of endocrinology and metabolic diseases for the treatment of metabolic disorders of University hospital Queen Giovanna – ISUL has been conducted.
All patients have been received daily 600 mg omega-3 fatty acids (360 mg EPA and 240 mg DHA/,120 mg koenzyme Q 10 and 46 mg selenium (product Omega prime) to recommended hypo lipid diet and increased physical activity. In all patients before and after treatment the clinical exam, questionnaire, anthropomorphic measurements, cardiovascular status and the serum hematologic, biochemical and metabolic indices have been performed. After of nutraceutical supplementation significant lipid serum amelioration – decreasing of total cholesterol with 9,38%, LDL-cholesterol with 19,49%, reaching the target level under 3 mmol/l , increasing of HDL-cholesterol with 7,62%, and decreasing of serum triglycerides with 41,92%, also reaching recommended target level under 1,5 mmol/l, have been established. In 77,27 % of patients C-reactive protein decreased with 32,92% and in 84% decreasing of insulin resistance index with 41,56%, have been founded. The clinical study results support the recommendation of nutraceutical approaches for the control, prevention and treatment of cardiovascular risk in patient with dyslipoproteinemias and metabolic syndrome.
Key words: nutraceuticals, omega-3, dyslipoproteinemias, metabolic syndrome
Address of correspondence:
Assoc. Prof. Dr. D. Popova, MD
Clinic of Endocrinology and Metabolic Diseases for
the Treatment of Metabolic Disorders, University Hospital „Tsaritsa Ioanna“ – ISUL, Medical University – Sofia
8 „Byalo More“, Str.
1527, Sofia
e-mail: danielapopovabg@yahoo.com